TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34908223

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg or 25 mg
Number of subjects: 1517

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1517
Study: 32783799

Group type: EXPERIMENTAL
Intervention: Antimicrobials (azithromycin and nitazoxanide)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nicotinamide (niacin vitamer)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risk factors for low enrollment weight
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neonatal serious adverse events
Number of subjects: 0
Study: 36273926

Group type: EXPERIMENTAL
Intervention: Rucaparib 600 mg twice daily
Number of subjects: 564

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 564
Study: 34082074

Group type: EXPERIMENTAL
Intervention: Individualized prescribing portraits mailed to family physicians
Number of subjects: 5157

Group type: COMPARATOR
Intervention: Delayed group (no immediate intervention)
Number of subjects: 5157
Study: 32028090

Group type: EXPERIMENTAL
Intervention: In-kind team incentives
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (no in-kind incentives)
Number of subjects: 75
Study: 35947348

Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg every 4 weeks (Q4W)
Number of subjects: 738

Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg every 8 weeks (Q8W)
Number of subjects: 738

Group type: COMPARATOR
Intervention: Placebo (crossover to guselkumab Q4W at Week 24)
Number of subjects: 738

Group type: EXPERIMENTAL
Intervention: Guselkumab (both Q4W and Q8W)
Number of subjects: 738
Study: 33892948

Group type: EXPERIMENTAL
Intervention: Baseline NAVA
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 50% of baseline NAVA
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 150% of baseline NAVA
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 100% of baseline NAVA
Number of subjects: 30

Group type: COMPARATOR
Intervention: Doubling PEEP
Number of subjects: 30
Study: 32694216

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 10142
Study: 33559434

Group type: EXPERIMENTAL
Intervention: Acupotomy combined with Xingnao Kaiqiao acupuncture therapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Xingnao Kaiqiao acupuncture therapy
Number of subjects: 80
Study: 32984901

Group type: EXPERIMENTAL
Intervention: Hybrid clinical decision support system (machine learning and rule-based expert system)
Number of subjects: 10716

Group type: COMPARATOR
Intervention: Computerized alerts generated by a clinical decision support (CDS) system
Number of subjects: 10716

Group type: COMPARATOR
Intervention: Literature-based multicriteria query prioritization technique
Number of subjects: 10716
Study: 36241145

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Education (UC + educational materials about cervical cancer screening)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Direct-Mail (UC + Education + a mailed self-sampling kit)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Opt-In (UC + Education + option to request a kit)
Number of subjects: 0
Study: 34844191

Group type: EXPERIMENTAL
Intervention: Next generation plasma protein profiling
Number of subjects: 50
Study: 35732279

Group type: EXPERIMENTAL
Intervention: FH01
Number of subjects: 41

Group type: COMPARATOR
Intervention: TT6m
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Both FH01 and TT6m
Number of subjects: 41
Study: 32706184

Group type: EXPERIMENTAL
Intervention: Porcine‐derived dermal collagen matrix (test site)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Connective tissue graft (control site)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Porcine‐derived dermal collagen matrix
Number of subjects: 20
Study: 35916880

Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation (eicosapentaenoic and docosahexaenoic acids)
Number of subjects: 436

Group type: COMPARATOR
Intervention: Placebo (refined olive oil)
Number of subjects: 436
Study: 34288070

Group type: EXPERIMENTAL
Intervention: Third-trimester routine ultrasound
Number of subjects: 1275
Study: 35970518

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25 μg
Number of subjects: 10355

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/violanterol (FF/VI) 100/25 μg
Number of subjects: 10355

Group type: COMPARATOR
Intervention: UMEC/VI 62.5/25 μg
Number of subjects: 10355

Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI
Number of subjects: 10355
Study: 34727465

Group type: EXPERIMENTAL
Intervention: 30 mg Dexamethasone (DXM)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no DXM or placebo)
Number of subjects: 45
Study: 33734138

Group type: EXPERIMENTAL
Intervention: EMPA-REG OUTCOME trial population
Number of subjects: 8389
Study: 32062847

Group type: EXPERIMENTAL
Intervention: Surgeon self-reported chemoprophylaxis practices
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Administered chemoprophylaxis
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Post-operative VTE dosing
Number of subjects: 66
Study: 33977571

Group type: EXPERIMENTAL
Intervention: Resorbable membrane (RES)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Non-resorbable membrane (N-RES)
Number of subjects: 27
Study: 32332670

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy at a wavelength of 808 nm, administered twice per week for a total of 12 sessions.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham treatment (simulated laser therapy), administered twice per week for a total of 12 sessions.
Number of subjects: 0
Study: 34450674

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided (USG) technique
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard single-wall puncture technique (Control)
Number of subjects: 100
Study: 35684041

Group type: EXPERIMENTAL
Intervention: Red orange extract (100 mg/day)
Number of subjects: 110
Study: 33400435

Group type: EXPERIMENTAL
Intervention: ShotBlocker (n = 47)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (n = 47)
Number of subjects: 94
Study: 35166034

Group type: EXPERIMENTAL
Intervention: PENS (10-Hz percutaneous electrical current stimulation)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham stimulation (same puncture method with no electric stimulation)
Number of subjects: 20
Study: 32897461

Group type: EXPERIMENTAL
Intervention: In-person training
Number of subjects: 46

Group type: COMPARATOR
Intervention: Video-based training
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both groups (In-person and Video-based)
Number of subjects: 46
Study: 35657581

Group type: EXPERIMENTAL
Intervention: CC-292 SDD tablet under fed conditions
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CC-292 SDD tablet after multiple doses of omeprazole (40 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CC-292 SDD formulation (100–300 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CC-292 under all conditions
Number of subjects: 24

Group type: COMPARATOR
Intervention: CC-292 under fed vs fasted conditions
Number of subjects: 24
Study: 34078380

Group type: EXPERIMENTAL
Intervention: Automated, patient-directed cancer genetics services delivery model
Number of subjects: 2780

Group type: COMPARATOR
Intervention: Enhanced standard of care cancer genetics services delivery model
Number of subjects: 2780
Study: 33328269

Group type: EXPERIMENTAL
Intervention: 20 mg praliciguat
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: 40 mg praliciguat
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Pooled praliciguat
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study: 35998952

Group type: COMPARATOR
Intervention: Medical treatment (MT)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Surgical haematoma evacuation (HE)
Number of subjects: 64
Study: 33451591

Group type: EXPERIMENTAL
Intervention: Gabapentin (1800-2400 mg/d)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Active comparator (ondansetron 24-32 mg/d or metoclopramide 45-60 mg/d)
Number of subjects: 31
Study: 32758179

Group type: EXPERIMENTAL
Intervention: Cancer group
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Comparison group (general population)
Number of subjects: 2000
Study: 33879709

Group type: EXPERIMENTAL
Intervention: Self-monitored walking (SM)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Supervised walking (SU)
Number of subjects: 42
Study: 33004730

Group type: EXPERIMENTAL
Intervention: 1% Clotrimazole (antifungal)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Normal saline with LASER
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sodium Hypochlorite
Number of subjects: 20
Study: 35579708

Group type: EXPERIMENTAL
Intervention: Non-commercial REDCap platform accessed via smartphone
Number of subjects: 0
Study: 33963971

Group type: COMPARATOR
Intervention: Single intravenous ascending doses of apitegromab (1, 3, 10, 20, 30 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multiple intravenous ascending doses of apitegromab (10, 20, 30 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single and multiple doses of apitegromab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Apitegromab
Number of subjects: 0
Study: 33176409

Group type: EXPERIMENTAL
Intervention: Ultrasound guided continuous lumbar plexus block (LPB) with 0.5% ropivacaine (15 mL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuous epidural anesthesia (CEA) with 0.5% ropivacaine (15 mL)
Number of subjects: 0
Study: 36268563

Group type: EXPERIMENTAL
Intervention: Recruitment strategies employed during the study
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maximizing recruiter availability, developing a responsive communication approach, demonstrating respect for facility procedures and operations, ensuring peak preparedness
Number of subjects: 0
Study: 33051215

Group type: EXPERIMENTAL
Intervention: Phenylephrine 1% and cyclopentolate 0.2% (treatment A)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Phenylephrine 0.5% and cyclopentolate 0.1% (treatment B)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 17
Study: 33072067

Group type: EXPERIMENTAL
Intervention: 8-IRG signature in the training cohort
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: 8-IRG signature
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Naive B cells, resting memory CD4 T cells, follicular helper T cells, and M2 macrophages
Number of subjects: 464

Group type: COMPARATOR
Intervention: High-risk cohort
Number of subjects: 464
Study: 34817543

Group type: EXPERIMENTAL
Intervention: Patient-led surveillance
Number of subjects: 100

Group type: COMPARATOR
Intervention: Clinician-led surveillance
Number of subjects: 100
Study: 34112640

Group type: EXPERIMENTAL
Intervention: Norwegian (n=64)
Number of subjects: 130

Group type: COMPARATOR
Intervention: English (n=66)
Number of subjects: 130
Study: 32633020

Group type: EXPERIMENTAL
Intervention: Greenlight laser vapo-enucleation of the prostate (GL.PVEP)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Holmium laser enucleation of the prostate (HoLEP)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Transurethral resection in saline (TURIS)
Number of subjects: 182
Study: 36008086

Group type: EXPERIMENTAL
Intervention: Preoperative PENG block
Number of subjects: 164

Group type: COMPARATOR
Intervention: Systemic analgesia alone
Number of subjects: 164
Study: 34794998

Group type: EXPERIMENTAL
Intervention: Patient-centred labels (PCL)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Standard labels
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Patient-centred labels (PCL) in low health literacy participants
Number of subjects: 121

Group type: COMPARATOR
Intervention: Standard labels in low health literacy participants
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Patient-centred labels (PCL) in low Rapid Estimate of Adult Literacy in Medicine scores
Number of subjects: 121

Group type: COMPARATOR
Intervention: Standard labels in low Rapid Estimate of Adult Literacy in Medicine scores
Number of subjects: 121
Study: 35662679

Group type: EXPERIMENTAL
Intervention: Imagery rescripting focused on the feared outcome of the behavioral experiment
Number of subjects: 60

Group type: COMPARATOR
Intervention: No imagery rescripting (control group)
Number of subjects: 60
Study: 32455002

Group type: EXPERIMENTAL
Intervention: Cashew nut seed flour (daily intake for 24 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 30
Study: 33853492

Group type: EXPERIMENTAL
Intervention: Discussed treatment goals with doctors (450 respondents, 38.9%)
Number of subjects: 1156

Group type: COMPARATOR
Intervention: Not discussed treatment goals (287 respondents, 24.8%)
Number of subjects: 1156

Group type: EXPERIMENTAL
Intervention: Biological agents
Number of subjects: 1156

Group type: EXPERIMENTAL
Intervention: Anti-RANKL antibodies
Number of subjects: 1156
Study: 33079955

Group type: EXPERIMENTAL
Intervention: Post-term pregnancies (PlGF)
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Post-term pregnancies (sFlt-1)
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Post-term pregnancies (sFlt-1/PlGF ratio)
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: PlGF below the 5th percentile
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: sFlt-1/PlGF ratio above the 95th percentile
Number of subjects: 426
Study: 34311206

Group type: EXPERIMENTAL
Intervention: Therapeutic workplace intervention (12 months with employment specialist)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Therapeutic workplace attendance during training (Phase 1)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Opiate- and cocaine-negative urine samples while seeking employment
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Unemployment status at study intake
Number of subjects: 91
Study: 34410195

Group type: EXPERIMENTAL
Intervention: Electronic informed consent (IC)
Number of subjects: 501

Group type: COMPARATOR
Intervention: Face-to-face informed consent (IC)
Number of subjects: 501
Study: 34215499

Group type: EXPERIMENTAL
Intervention: Aggressive intravenous hydration (20 ml/kg bolus followed by 3 ml/kg/hr)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard intravenous hydration (10 ml/kg bolus followed by 1.5 ml/kg/hr)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Aggressive intravenous hydration in obese patients
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard intravenous hydration in obese patients
Number of subjects: 44
Study: 32970730

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Community health services
Number of subjects: 52
Study: 35770993

Group type: EXPERIMENTAL
Intervention: 10-kHz spinal cord stimulation (SCS)
Number of subjects: 0
Study: 34464522

Group type: EXPERIMENTAL
Intervention: Guided internet-based self-help program
Number of subjects: 402

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 402
Study: 34101004

Group type: EXPERIMENTAL
Intervention: Self-selected high-protein low-carbohydrate diet for 24 weeks
Number of subjects: 28
Study: 32558773

Group type: EXPERIMENTAL
Intervention: Left atrial emptying fraction (LAEF) measured by cardiac CT
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Left atrial minimal volume (LAmin)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Combination of LAEF and LAmin volume
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Passive LAEF
Number of subjects: 92
Study: 36082969

Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 391

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 391
Study: 32642847

Group type: EXPERIMENTAL
Intervention: 3D vision
Number of subjects: 40

Group type: COMPARATOR
Intervention: 2D vision
Number of subjects: 40
Study: 32468956

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus etoposide and platinum (EP)
Number of subjects: 453

Group type: COMPARATOR
Intervention: Placebo plus etoposide and platinum (EP)
Number of subjects: 453
Study: 35440501

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/day
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Eplerenone 50 mg/day
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Dapagliflozin and Eplerenone combination
Number of subjects: 46

Group type: COMPARATOR
Intervention: Eplerenone
Number of subjects: 46
Study: 34133509

Group type: EXPERIMENTAL
Intervention: Levetiracetam (titrated from 20 mg/kg/day or 1,000 mg/day up to 60 mg/kg/day or 3,000 mg/day)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study: 32811460

Group type: EXPERIMENTAL
Intervention: Obesity Prevention Group (OPG) - anticipatory guidance on responsive feeding and care practices, with six home visits by a peer educator.
Number of subjects: 430

Group type: COMPARATOR
Intervention: Injury Prevention Group (IPG) - anticipatory guidance on child safety, with partners only completing study assessments, also receiving six home visits by a peer educator.
Number of subjects: 430
Study: 35232232

Group type: EXPERIMENTAL
Intervention: Scientific messaging endorsing the vaccine
Number of subjects: 2037

Group type: COMPARATOR
Intervention: Partisan messaging endorsing the vaccine
Number of subjects: 2037
Study: 32291547

Group type: EXPERIMENTAL
Intervention: Bone-anchored expander (KLS Martin®)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Tooth-borne expander (Hyrax®)
Number of subjects: 24
Study: 35775864

Group type: EXPERIMENTAL
Intervention: Tissue adhesive (N-BCA + OCA; Iceberg-glue®)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Surgical sutures (0/5 nylon sutures)
Number of subjects: 12
Study: 34538401

Group type: EXPERIMENTAL
Intervention: Adaptive trial design evaluating multiple agents in RCC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Collaboration between academia and industry for trial design
Number of subjects: 0
Study: 34971796

Group type: EXPERIMENTAL
Intervention: Usual care with LCS navigation (n = 200)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Usual care without LCS navigation (n = 100)
Number of subjects: 300
Study: 34535071

Group type: EXPERIMENTAL
Intervention: 1 K SNP chip
Number of subjects: 250
Study: 36093704

Group type: EXPERIMENTAL
Intervention: Micronutritional supplementation (1g fish oil with 500mg DHA, 150mg EPA; 22mg carotenoids; 15mg vitamin E)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Micronutritional supplementation
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 32305122

Group type: EXPERIMENTAL
Intervention: Laser ablation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mechanochemical ablation
Number of subjects: 0
Study: 34283183

Group type: EXPERIMENTAL
Intervention: Canakinumab (450 mg for body weight of 40‐<60 kg, 600 mg for 60‐80 kg, and 750 mg for >80 kg; n=227)
Number of subjects: 454

Group type: COMPARATOR
Intervention: Placebo (n=227)
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Canakinumab
Number of subjects: 454

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 454
Study: 33444205

Group type: EXPERIMENTAL
Intervention: Food insecurity (FI) prevalence
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: No formal education
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: No income-generating activities
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: No home gardening practice
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: Alcohol use by husbands
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: Low minimum dietary diversity score
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: Less than three frequencies of meals
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: Three meals only per day
Number of subjects: 612
Study: 34406244

Group type: EXPERIMENTAL
Intervention: Transcutaneous Electric Nerve Stimulation (100 Hz, 200 μs)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 23
Study: 35724467

Group type: EXPERIMENTAL
Intervention: Etoricoxib (60 mg, Day 1 to Day 8)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control (no prophylactic treatment)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Etoricoxib
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control
Number of subjects: 144
Study: 32650223

Group type: EXPERIMENTAL
Intervention: Intervention group (weight loss program)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Usual care group (control)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Baseline SCS
Number of subjects: 47
Study: 35903009

Group type: EXPERIMENTAL
Intervention: Fluoxetine (10 mg)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 34006926

Group type: EXPERIMENTAL
Intervention: Anlotinib 12 mg orally once daily for 14 days every 3 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 32909491

Group type: EXPERIMENTAL
Intervention: In-person training
Number of subjects: 441

Group type: COMPARATOR
Intervention: Virtual tele-mentoring
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Training (both methods)
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: SOuND practices
Number of subjects: 441
Study: 36269383

Group type: EXPERIMENTAL
Intervention: Matrix‐associated autologous chondrocyte implantation (ACI) using spheroids (n=52)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Microfracture (n=50)
Number of subjects: 102
Study: 34474735

Group type: EXPERIMENTAL
Intervention: Renal Denervation (RDN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham Control
Number of subjects: 0
Study: 36346543

Group type: EXPERIMENTAL
Intervention: Pharmacist-led intervention involving referral to treating physician for therapy intensification.
Number of subjects: 497

Group type: COMPARATOR
Intervention: Control group (AOBP recorded until the end of the trial).
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control).
Number of subjects: 497
Study: 33576770

Group type: EXPERIMENTAL
Intervention: Higher supine systolic blood pressure
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Higher supine diastolic blood pressure
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Higher augmentation index
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Central systolic pressure and arterial stiffness indicators (including pulse wave velocity, central pulse pressure, and peripheral pulse pressure)
Number of subjects: 231